Quick Answer
Merck & Co., Inc. reported Cash and Equivalents of $14.56 billion for fiscal year 2025.
Merck & Co., Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $14.56B | +10.0% |
| 2024 | $13.24B | +93.6% |
| 2023 | $6.84B | -46.1% |
| 2022 | $12.69B | +56.8% |
| 2021 | $8.10B | +0.6% |
| 2020 | $8.05B | -16.8% |
| 2019 | $9.68B | +21.5% |
| 2018 | $7.96B | +30.7% |
| 2017 | $6.09B | -6.5% |
| 2016 | $6.51B | -23.6% |
| 2015 | $8.52B | +14.6% |
| 2014 | $7.44B | -52.4% |
| 2013 | $15.62B | +16.1% |
| 2012 | $13.45B | -0.6% |
| 2011 | $13.53B | +24.1% |
| 2010 | $10.90B | +17.1% |
| 2009 | $9.31B | +113.2% |
| 2008 | $4.37B | -18.1% |
| 2007 | $5.34B | -9.8% |
| 2006 | $5.91B | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $18.17B | +24.5% | +126.9% |
| June 30, 2025 | $8.01B | -29.2% | -7.2% |
| March 31, 2025 | $8.63B | +54.7% | -34.8% |
| December 31, 2024 | $13.24B | +93.6% | -9.3% |
| September 30, 2024 | $14.59B | +69.6% | +29.1% |
| June 30, 2024 | $11.30B | +99.7% | +102.6% |
| March 31, 2024 | $5.58B | -42.5% | -18.4% |
| December 31, 2023 | $6.84B | -46.1% | -20.5% |
- Merck & Co., Inc. showed an increase of +10.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2006–2025 period, Merck & Co., Inc.’s cash and equivalents has grown by 146.3% (from $5.91 billion to $14.56 billion).
- The most recent figure is from Merck & Co., Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: